UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The role of hypoxia in pancreatic cancer: a potential therapeutic target?

Expert review of gastroenterology & hepatology, 2016-03, Vol.10 (3), p.301-316

2016

Volltextzugriff (PDF)

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma

Leukemia, 2021-03, Vol.35 (3), p.752-763

2021

Volltextzugriff (PDF)

2-Deoxy-d-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion

Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.899-910

2011

Volltextzugriff (PDF)

Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation

Molecular cancer therapeutics, 2007-11, Vol.6 (11), p.3049-3058

2007

Volltextzugriff (PDF)

Activation of the Unfolded Protein Response by 2-Deoxy-d-Glucose Inhibits Kaposi's Sarcoma-Associated Herpesvirus Replication and Gene Expression

Antimicrobial Agents and Chemotherapy, 2012-11, Vol.56 (11), p.5794-5803

2012

Volltextzugriff (PDF)

Antiangiogenic activity of 2-deoxy-D-glucose

PloS one, 2010-10, Vol.5 (10), p.e13699

2010

Volltextzugriff (PDF)

Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-d-glucose

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.732-741

2007

Volltextzugriff (PDF)

Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-d-glucose under hypoxia in lung cancer cell lines

Molecular cancer therapeutics, 2008-06, Vol.7 (6), p.1506-1513

2008

Volltextzugriff (PDF)

Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing hypoxic tumor cells

Cancer chemotherapy and pharmacology, 2006-12, Vol.58 (6), p.725-734

2006

Volltextzugriff (PDF)

GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells

Cell cycle (Georgetown, Tex.), 2009-10, Vol.8 (19), p.3149-3156

2009

Volltextzugriff (PDF)

The wonders of 2‐deoxy‐d‐glucose

IUBMB life, 2014-02, Vol.66 (2), p.110-121

2014

Volltextzugriff (PDF)

Performance of a moment resisting beam-column connection for precast concrete construction

Engineering structures, 2021-11, Vol.246, p.113005, Article 113005

2021

Volltextzugriff (PDF)

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

Lancet neurology, 2023-07, Vol.22 (7), p.578-590

2023

Volltextzugriff (PDF)

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2013-02, Vol.71 (2), p.523-530

2013

Volltextzugriff (PDF)

Getting It Off Her Chest: A Case of an Anterior Mediastinal Mass

Chest, 2013, Vol.144 (4), p.104A-104B

2013

Volltextzugriff (PDF)

Safety and Efficacy of Autologous RNA Chimeric Antigen Receptor T-cell (rCAR-T) Therapy in Myasthenia Gravis: a prospective, multicenter, open-label, non-randomised phase 1b/2a study

Lancet neurology, 2023-07, Vol.22 (7), p.578-590

2023

Volltextzugriff (PDF)

Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells

Antioxidants & redox signaling, 2007-09, Vol.9 (9), p.1383-1390

2007

Volltextzugriff (PDF)

A novel functional CT contrast agent for molecular imaging of cancer

Physics in medicine & biology, 2010-08, Vol.55 (15), p.4389-4397

2010

Volltextzugriff (PDF)

Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.1811-1811

2019

Volltextzugriff (PDF)

Targeting cisplatin-resistant human tumor cells with metabolic inhibitors

Cancer chemotherapy and pharmacology, 2014-02, Vol.73 (2), p.417-427

2014

Volltextzugriff (PDF)

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1–expressing myeloma cells

Blood, 2011-08, Vol.118 (5), p.1329-1339

2011

Volltextzugriff (PDF)

Unleashing the full potential of cell therapy through RNA engineering

Cell and Gene Therapy Insights, 2022-05, Vol.8 (4), p.455-461

Kurtoglu, Metin

2022

Volltextzugriff (PDF)

From delocalized lipophilic cations to hypoxia: Blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors

Molecular nutrition & food research, 2009, Vol.53 (1), p.68-75

2009

Volltextzugriff (PDF)

AuNP-DG: Deoxyglucose-Labeled Gold Nanoparticles as X-ray Computed Tomography Contrast Agents for Cancer Imaging

Molecular imaging and biology, 2010-10, Vol.12 (5), p.463-467

2010

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(62)

Publikationsform

Sprache

Englisch
(68)
Türkisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The role of hypoxia in pancreatic cancer: a potential therapeutic target?

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma

2-Deoxy-d-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion

Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation

Activation of the Unfolded Protein Response by 2-Deoxy-d-Glucose Inhibits Kaposi's Sarcoma-Associated Herpesvirus Replication and Gene Expression

Antiangiogenic activity of 2-deoxy-D-glucose

Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-d-glucose

Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-d-glucose under hypoxia in lung cancer cell lines

Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing hypoxic tumor cells

GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells

The wonders of 2‐deoxy‐d‐glucose

Performance of a moment resisting beam-column connection for precast concrete construction

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

Getting It Off Her Chest: A Case of an Anterior Mediastinal Mass

Safety and Efficacy of Autologous RNA Chimeric Antigen Receptor T-cell (rCAR-T) Therapy in Myasthenia Gravis: a prospective, multicenter, open-label, non-randomised phase 1b/2a study

Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells

A novel functional CT contrast agent for molecular imaging of cancer

Preclinical Evaluation of CD8+ Anti-Bcma mRNA CAR T-Cells for the Control of Human Multiple Myeloma

Targeting cisplatin-resistant human tumor cells with metabolic inhibitors

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1–expressing myeloma cells

Unleashing the full potential of cell therapy through RNA engineering

Global variability of the human IgG glycome

From delocalized lipophilic cations to hypoxia: Blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors

AuNP-DG: Deoxyglucose-Labeled Gold Nanoparticles as X-ray Computed Tomography Contrast Agents for Cancer Imaging

Suchergebnisse filtern